This approval offers a promising new targeted treatment for patients aged 12 and older with C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (IC-MPGN), ...

Alterity’s cash position on 30 June 2025 was A$40.66M with operating cash outflows for the quarter of A$2.35M. In accordance with ASX Listing Rule 4.7C, payments of A$119k made to related parties and ...

Alterity Therapeutics has reported positive topline results from its open-label phase II clinical trial of lead drug ATH434, ...

Data are Consistent with Phase 2 Double-Blind Trial and Support Advancement of ATH434 in MSA – MELBOURNE, Australia and SAN FRANCISCO, (GLOBE NEWSWIRE) -- Alterity Therapeutics (ASX: ATH, NASDAQ: ...

Proven efficacy across all three key markers of disease—68% reduction in proteinuria, stabilization of kidney function, and ...

Jack Rader, 6-4, 270-pound defensive lineman for the Bath Wildcats, picked up his fourth college offer last week from the ...

The top catchers from NCAA baseball and softball, along with the top catchers from select states in Reds Country, were ...

SuperSport anchor Julia Stuart shared breathtaking photos from her Monaco vacation with Maphuthi Hlako, leaving fans gushing ...

Approval is based on results from the Phase III VALIANT trial (NCT05067127), in which Empaveli demonstrated a 68% reduction ...

South Africa’s Independent Institute of Education (IIE), the country’s largest private higher education provider, has ...

The Independent Institute of Education is rolling out the D2L Brightspace learning management system, benefitting more than ...